These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15983919)

  • 1. Outcomes for patients receiving antiretroviral therapy in the developing world appear to be not much different from those in the developed world.
    del Rio C; Priddy F
    Clin Infect Dis; 2005 Jul; 41(2):225-6. PubMed ID: 15983919
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world?
    Lawn SD; Myer L; Wood R
    Clin Infect Dis; 2005 Dec; 41(11):1683-4; author reply 1684. PubMed ID: 16267745
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiretroviral resistance in the developing world.
    Pillay D
    J HIV Ther; 2007 Dec; 12(4):95-6. PubMed ID: 18578091
    [No Abstract]   [Full Text] [Related]  

  • 4. [HIV-treatment in Denmark and Africa--a world of differences].
    Ullum H; Søndergaard SR; Skinhøj P
    Ugeskr Laeger; 2000 Aug; 162(35):4641-3. PubMed ID: 10986888
    [No Abstract]   [Full Text] [Related]  

  • 5. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world.
    Bennett DE
    Curr Opin Infect Dis; 2006 Dec; 19(6):607-14. PubMed ID: 17075338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV resistance and the developing world.
    Gupta RK; Pillay D
    Int J Antimicrob Agents; 2007 May; 29(5):510-7. PubMed ID: 17346940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of HIV therapies in different economic worlds.
    Laurence J
    AIDS Read; 2001 May; 11(5):236-7. PubMed ID: 11392685
    [No Abstract]   [Full Text] [Related]  

  • 9. New approaches and resolve may define the future of the global HIV pandemic.
    Daar ES
    Res Initiat Treat Action; 2007; 12(2):8-10. PubMed ID: 17486706
    [No Abstract]   [Full Text] [Related]  

  • 10. About 1 million people in developing countries now receive HIV medications. Achievement falls short of WHO's '3 by 5'.
    AIDS Alert; 2005 Aug; 20(8):suppl 3-4. PubMed ID: 16124117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WHO launches guidelines to speed up delivery of antiretroviral drugs to HIV/AIDS patients.
    Bull World Health Organ; 2003; 81(11):852-3. PubMed ID: 14758421
    [No Abstract]   [Full Text] [Related]  

  • 12. AIDS in the Third World: how to stop the HIV infection?
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three million HIV/AIDS sufferers could receive anti-retroviral therapy by 2005: new hope for those in developing world.
    Lepr Rev; 2002 Sep; 73(3):295-6. PubMed ID: 12449898
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
    Manosuthi W; Sungkanuparph S; Thakkinstian A; Rattanasiri S; Chaovavanich A; Prasithsirikul W; Likanonsakul S; Ruxrungtham K
    Clin Infect Dis; 2006 Jul; 43(2):253-5. PubMed ID: 16779754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
    Renaud-Théry F; Nguimfack BD; Vitoria M; Lee E; Graaff P; Samb B; Perriëns J
    AIDS; 2007 Jul; 21 Suppl 4():S89-95. PubMed ID: 17620758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating HIV in the developing world: getting ahead of the drug development curve.
    Ford N; Calmy A; von Schoen-Angerer T
    Drug Discov Today; 2007 Jan; 12(1-2):1-3. PubMed ID: 17198967
    [No Abstract]   [Full Text] [Related]  

  • 17. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?
    Bagchi S; Kempf MC; Westfall AO; Maherya A; Willig J; Saag MS
    Clin Infect Dis; 2007 Jan; 44(1):135-8. PubMed ID: 17143829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balancing pills and patents: intellectual property and the HIV/AIDS crisis.
    Nderitu T
    E Law; 2001 Sep; 8(3):E5. PubMed ID: 16903022
    [No Abstract]   [Full Text] [Related]  

  • 19. The future of HIV vasculopathy when our patients are on antiretroviral therapy.
    Barry R
    S Afr J Surg; 2009 May; 47(2):58, 60. PubMed ID: 19626782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Médecins Sans Frontières (MSF) antiretroviral treatment projects worldwide.
    GMHC Treat Issues; 2003; 17(7-8):7. PubMed ID: 14686313
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.